Aktie A4081N EUROFARMA LABORATÓRIOS S.A.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Eurofarma Laboratórios S.A.

Aktien

A4081N

BREUFAACNOR4

EUFA3

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eurofarma Laboratórios S.A. acquired Genfar S.A. from Sanofi.
Abcuro, Inc. announced that it has received $155 million in funding from a group of investors
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Abcuro, Inc. announced that it expects to receive $199.522752 million in funding from Redmile Group, LLC, and other investors
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
Eurofarma Laboratórios S.A. agreed to acquire Genfar S.A. from Sanofi for approximately ?300 million.
Eurofarma Laboratórios S.A. acquired Laboratório Canonne for BRL 725 million.
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2021
Pfizer Inc. and BioNTech SE Announce Collaboration with Eurofarma Laboratórios SA to Manufacture COVID-19 Vaccine Doses for Latin America
Eurofarma Laboratórios S.A. cancelled the acquisition of a portfolio of 12 products in Latin America from Hypera S.A..
Eurofarma Laboratórios S.A. entered into agreement to acquire A portfolio of 12 products in Latin America from Hypera S.A. for approximately $160 million.
Biotoscana Confirms Divestiture Negotiations
Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries Through Extended Agreement with Eurofarma Laboratórios
Eurofarma Laboratórios S.A. acquired factory in Argentina of Sanofi.
Melinta Therapeutics, Inc. Partners with Eurofarma Laboratorios S.A
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A4081N Aktie
  4. Nachrichten Eurofarma Laboratórios S.A.
  5. Andere Sprachen